Cinzia Costa

Perugia, 06123, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 100 publications

SINEUP-Mediated Overexpression of Endogenous α-Amylase as a Therapeutic Approach in Lafora Disease.

SINEUP-Mediated Overexpression of Endogenous α-Amylase as a Therapeutic Approach in Lafora Disease.

Journal: Genes

Published: February 06, 2026

Soticlestat for drug-resistant epilepsy: Current evidence and clinical perspectives.

Soticlestat for drug-resistant epilepsy: Current evidence and clinical perspectives.

Journal: Seizure

Published: January 30, 2026

Immune profiling unveils the systemic cytokine milieu associated with acute reversible encephalopathy with cytotoxic lesions of the corpus callosum (CLOCCs).

Immune profiling unveils the systemic cytokine milieu associated with acute reversible encephalopathy with cytotoxic lesions of the corpus callosum (CLOCCs).

Journal: Journal of neuroimmunology

Published: September 20, 2025

Epm2bP71A and Epm2bD148N knock-in mouse models of Lafora disease exhibit distinct and pronounced neurological alterations.

Epm2bP71A and Epm2bD148N knock-in mouse models of Lafora disease exhibit distinct and pronounced neurological alterations.

Journal: Progress in neurobiology

Published: August 26, 2025

Epm2bP71A and Epm2bD148N knock-in mouse models of Lafora disease exhibit distinct and pronounced neurological alterations.

Epm2bP71A and Epm2bD148N knock-in mouse models of Lafora disease exhibit distinct and pronounced neurological alterations.

Journal: Progress in neurobiology

Published: August 26, 2025

Sleep disturbances are common in late-onset epilepsy of unknown origin.

Sleep disturbances are common in late-onset epilepsy of unknown origin.

Journal: Epileptic disorders : international epilepsy journal with videotape

Published: July 10, 2025

Advances in gene therapy for Lafora disease: Intravenous recombinant adeno-associated virus-mediated delivery of EPM2A and EPM2B genes.

Advances in gene therapy for Lafora disease: Intravenous recombinant adeno-associated virus-mediated delivery of EPM2A and EPM2B genes.

Journal: Clinical and translational medicine

Published: July 01, 2025

Neuronal hyperexcitability: A key to unraveling hippocampal synaptic dysfunction in Lafora disease.

Neuronal hyperexcitability: A key to unraveling hippocampal synaptic dysfunction in Lafora disease.

Journal: Epilepsia

Published: June 23, 2025

Etiological diagnosis of late-onset epilepsy: A key priority for Italian epileptologists - Insights from a LICE survey.

Etiological diagnosis of late-onset epilepsy: A key priority for Italian epileptologists - Insights from a LICE survey.

Journal: Epilepsia open

Published: May 12, 2025

Enhancing the quality and reproducibility of research: Preferred Evaluation of Cognitive and Neuropsychological Studies - The PECANS statement for human studies.

Enhancing the quality and reproducibility of research: Preferred Evaluation of Cognitive and Neuropsychological Studies - The PECANS statement for human studies.

Journal: Behavior research methods

Published: May 02, 2025

Immune control of the basal ganglia network: Interleukin-17 as a key modulator of striatal synaptic plasticity.

Immune control of the basal ganglia network: Interleukin-17 as a key modulator of striatal synaptic plasticity.

Journal: Neurobiology of disease

Published: February 02, 2025

Oligomeric alpha-synuclein causes early synaptic dysfunction of the corticostriatal pathway associated with non-motor symptoms.

Oligomeric alpha-synuclein causes early synaptic dysfunction of the corticostriatal pathway associated with non-motor symptoms.

Journal: NPJ Parkinson's disease

Published: January 14, 2025

Showing 1-12 of 100

Last Updated: 09/26/2026